Skip to content

Insider · CIK 0001994049

Martine Zimmermann

director

Files at LGND (LIGAND PHARMACEUTICALS INC), CADL (Candel Therapeutics, Inc.). First filing Sep 14, 2026, latest Sep 14, 2026.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $342k sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

LGND: LIGAND PHARMACEUTICALS INC

LGNDOct 9, 2026 · close 301.81

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
43Moderate
LGNDsell 2
LIGAND PHARMACEUTICALS INC
$342k
1,200 shares
-24%-

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Sep 22, 2026LGND
LIGAND PHARMACEUTICALS INC
FTax withholding
Common Stock
-115$298.50$34k3,78218 d ago
Sep 10, 2026LGND
LIGAND PHARMACEUTICALS INC
SOpen-market sale
Common Stock
-1,200$285.00$342k3,89728 d ago
Sep 8, 2026CADL
Candel Therapeutics, Inc.
AGrant or award
Stock Option (Right to Buy)derivative
+64,000$0.00$064,00032 d ago
Sep 22, 2025LGND
LIGAND PHARMACEUTICALS INC
FTax withholding
Common Stock
-115$170.77$20k4,443Sep 24, 2025
Jun 6, 2025LGND
LIGAND PHARMACEUTICALS INC
AGrant or award
Common Stock
+1,209$0.00$04,746Jun 10, 2025
Jun 6, 2025LGND
LIGAND PHARMACEUTICALS INC
FTax withholding
Common Stock
-188$105.99$20k4,558Jun 10, 2025
Jun 6, 2025LGND
LIGAND PHARMACEUTICALS INC
AGrant or award
Non-Qualified Stock Option (right to buy)derivative
+5,783$0.00$05,783Jun 10, 2025

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Martine Zimmermann: insider trades and track record | InsiderTell